LINCOMYCIN SXP lincomycin (as hydrochloride monohydrate) 600 mg/2mL solution for injection ampoule

Ország: Ausztrália

Nyelv: angol

Forrás: Department of Health (Therapeutic Goods Administration)

Aktív összetevők:

lincomycin hydrochloride monohydrate, Quantity: 680.4 mg (Equivalent: lincomycin, Qty 600 mg)

Beszerezhető a:

Southern XP IP Pty Ltd

Gyógyszerészeti forma:

Injection, solution

Összetétel:

Excipient Ingredients: benzyl alcohol; water for injections

Az alkalmazás módja:

Intramuscular, Intravenous

db csomag:

5

Recept típusa:

(S4) Prescription Only Medicine

Terápiás javallatok:

Lincomycin SXP is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. Because of the risk of colitis (see PRECAUTIONS), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,Lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. Staphylococcal strains resistant to Lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with Lincomycin injection therapy. In the case of macrolides, partial but not complete cross resistance may occur. The drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see PRECAUTIONS).,The specific infections for which Lincomycin SXP is indicated are as follows:,Upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. Effectiveness in the treatment of mastoiditis would be anticipated.,Lower respiratory infections including acute and chronic bronchitis and pneumonia.,Skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. Conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,Bone and joint infections including osteomyelitis and septic arthritis.,Septicaemia and endocarditis. Selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. However, bactericidal drugs are often preferred for these infections.,Bacillary Dysentery. Although Shigella is resistant to lincomycin in vitro (MIC approximately 200-400 micrograms/mL), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Termék összefoglaló:

Visual Identification: Clear, colorless to slightly yellow solution, having a slight odour, essentially free from visible particulate matter.; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure and restricted flow insert

Engedélyezési státusz:

Registered

Engedély dátuma:

2017-12-04

Betegtájékoztató

1
LINCOMYCIN SXP
_lincomycin hydrochloride monohydrate_
_ _
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
Please read this leaflet carefully
before you start using
LINCOMYCIN SXP. This leaflet
answers some common questions
about LINCOMYCIN SXP. It does
not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you using
LINCOMYCIN SXP against the
benefits it is expected to have for
you. Use LINCOMYCIN SXP as
instructed and follow the advice
given in this leaflet.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
Keep this leaflet with your
medicine. You may need to read it
again.
WHAT LINCOMYCIN
SXP IS USED FOR
LINCOMYCIN SXP is an antibiotic
used to treat serious infections in
different parts of the body caused by
certain bacteria. LINCOMYCIN
SXP works by killing or stopping
the growth of bacteria causing your
infection.
The specific infections for which
LINCOMYCIN SXP is used
include: ear, throat and lung
infections; skin infections; bone and
joint infections; and infections of the
blood.
LINCOMYCIN SXP will not work
against viral infections such as colds
or flu.
Your doctor may have prescribed
LINCOMYCIN SXP for another
reason.
Ask your doctor if you have any
questions about why LINCOMYCIN
SXP has been prescribed for you.
This medicine is available only with
a doctor's prescription.
LINCOMYCIN SXP is not
addictive.
BEFORE YOU USE
LINCOMYCIN SXP
Some information is provided below.
However, always talk to your doctor
if you have concerns or questions
about your treatment.
_WHEN YOU MUST NOT USE _
_LINCOMYCIN SXP_
DO NOT USE LINCOMYCIN SXP IF:
1.
YOU HAVE AN ALLERGY TO:
•
CLINDAMYCIN OR LINCOMYCIN
•
ANY OF THE OTHER INGREDIENTS
LISTED AT THE END OF THIS LEAFLET
(see 'Product Description')
Symptoms of an allergic reaction
may include skin rash, itching or
difficulty in breathing, wheezing
or coughing (anaphylactic
reactions). If you are not su

Termékjellemzők

1
AUSTRALIAN PRODUCT INFORMATION – LINCOMYCIN SXP (LINCOMYCIN
HYDROCHLORIDE) SOLUTION FOR INJECTION
1
NAME OF THE MEDICINE
Lincomycin Hydrochloride
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each mL contains lincomycin hydrochloride monohydrate equivalent to
lincomycin base 300 mg.
Excipients with known effect:
Benzyl alcohol 9.45 mg
For the full list of excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
Solution for injection
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
Lincomycin SXP is indicated in the treatment of serious infections due
to susceptible strains of gram-
positive aerobes such as streptococci, pneumococci and staphylococci.
Its use should be reserved for penicillin-allergic patients or other
patients for whom, in the
judgement of the physician, a penicillin is inappropriate. Because of
the risk of colitis (See section
4.4, Special Warnings and Precautions for Use), before selecting
lincomycin the physician should
consider the nature of infection and the suitability of less toxic
alternatives (e.g. erythromycin).
Lincomycin injection has been demonstrated to be effective in the
treatment of staphylococcal
infections resistant to other antibiotics and susceptible to
lincomycin. Staphylococcal strains
resistant to Lincomycin injection have been recovered; culture and
susceptibility studies should be
done in conjunction with Lincomycin injection therapy. In the case of
macrolides, partial but not
complete cross resistance may occur. The drug may be administered
concomitantly with other
antimicrobial agents with which it is compatible when indicated (See
section 4.4, Special Warnings
and Precautions for Use).
The specific infections for which Lincomycin SXP is indicated are as
follows:
•
Upper respiratory infections including tonsillitis, pharyngitis,
otitis media, sinusitis, scarlet
fever and as adjuvant therapy for diphtheria. Effectiveness in the
treatment of mastoiditis
would be anticipated.
•
Lower respiratory infections including acute and chronic bronchitis
and p